These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3211990)

  • 1. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man.
    Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD
    J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disopyramide pharmacokinetics and metabolism: effect of inducers.
    Kapil RP; Axelson JE; Mansfield IL; Edwards DJ; McErlane B; Mason MA; Lalka D; Kerr CR
    Br J Clin Pharmacol; 1987 Dec; 24(6):781-91. PubMed ID: 3440098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of a disopyramide metabolite in renal failure.
    Inagaki Y; Amano I; Otsu T
    ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of age and smoking on the elimination of disopyramide.
    Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
    Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
    Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
    Hasselström J; Enquist M; Hermansson J; Dahlqvist R
    Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
    Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
    Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.
    Iisalo E; Aaltonen L
    Br J Clin Pharmacol; 1984 Mar; 17(3):325-9. PubMed ID: 6712865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct enantiomeric resolution of disopyramide and its metabolite using chiral high-performance liquid chromatography. Application to stereoselective metabolism and pharmacokinetics of racemic disopyramide in man.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    J Chromatogr; 1988 Oct; 450(2):211-6. PubMed ID: 3235589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.